TY - JOUR
T1 - Improving community health-care systems’ early detection of cognitive decline and dementia
AU - PAD 20/20 Work Group on Community-Based Detection of Cognitive Decline and Dementia
AU - Au, Rhoda
AU - Ferrell, Phyllis Barkman
AU - Beeri, Michal
AU - Boden-Albala, Bernadette
AU - Frank, Lori
AU - Jimenez-Maggiora, Gustavo
AU - Khachaturian, Ara
AU - Kirkendall, Eric
AU - Kivipelto, Miia
AU - Larson, Eric
AU - Mattke, Soren
AU - Mielke, Michelle
AU - Paschalidis, Ioannis
AU - Readhead, Benjamin
AU - Schnitzler, Peter
AU - Schultze, Joachim
AU - Tang, Yi
AU - Teipel, Stefan
AU - Williamson, Jeff
AU - Zabar, Yuval
N1 - Funding Information:
Work group members and panelists: Rhoda Au, Ph.D., Anatomy & Neurobiology, Boston University School of Medicine, rhodaau@bu.edu Phyllis Barkman Ferrell, Ph.D., Eli Lilly & Company, phyl@lilly.com Michal Beeri, Ph.D., Joseph Sagol Neuroscience Center, Sheba University, michal.beeri@mssm.edu Bernadette Boden-Albala, Ph.D., Department of Health, Society and Behavior, Program in Public Health, University of California, Irvine, bbodenal@uci.edu Lori Frank, Ph.D., New York Academy of Medicine, LFrank@nyam.org Gustavo Jimenez-Maggiora, Ph.D., Alzheimer's Therapeutic Research Institute, University of Southern California, gustavoj@usc.edu Ara Khachaturian, Ph.D, Campaign to Prevent Alzheimer's disease, ara@pad2020.org Eric Kirkendall, M.D., Wake Forest School of Medicine, ekirkend@wakehealth.edu Miia Kivipelto, M.D., Ph.D., Karolinska Institutet Center for Alzheimer Research, Miia.Kivipelto@ki.se Eric Larson, M.D., M.P.H., Kaiser Permanente Washington Health Research Institute, University of Washington, larson.e@ghc.org Soren Mattke, M.D., D.Sc., Center for Improving Chronic Illness Care, University of Southern California, mattke@usc.edu Michelle Mielke, Ph.D., Department of Epidemiology, Wake Forest School of Medicine, mmielke@wakehealth.edu Ioannis Paschalidis, Ph.D., Center for Information and Systems Engineering, Boston University College of Engineering, yannisp@bu.edu Benjamin Readhead, M.D., Arizona State University Biodesign Institute, ben.readhead@gmail.com Peter Schnitzler, Ph.D., Eli Lilly & Company, schnitzler_peter_j@lilly.com Joachim Schultze, M.D., Ph.D., Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Joachim.schultze@dzne.de Yi Tang, M.D., Ph.D., Innovation Center for Neurological Disorders at Xuanwu Hospital Capital Medical University, tangyixw@163.com Stefan Teipel, M.D., German Center for Neurodegenerative Diseases (DZNE), University of Rostock, stefan.teipel@med.uni-rostock.de Jeff Williamson, M.D., Atrium Health and Wake Forest School of Medicine, jwilliam@wakehealth.edu Yuval Zabar, M.D., Biogen, yuval.zabar@biogen.com
Publisher Copyright:
© 2022 the Alzheimer's Association.
PY - 2022/11
Y1 - 2022/11
N2 - Preliminary estimates suggest that current global health-care systems lack the resource capacity to provide persons with dementia timely access to diagnosis, treatment, and care. There is an increasing need to improve timely identification of individuals who will likely progress to Alzheimer's disease (AD) dementia particularly among under-represented, underserved, and vulnerable populations. The rapidly evolving area of bioinformatics of health system data and the emergence of fluid-based biomarkers for pre-symptomatic AD may provide an innovative strategic option for health system planners. A think-tank style meeting entitled “The Campaign to Prevent Alzheimer's Disease Work Group on Community-Based Detection and Assessment of Cognitive Decline” developed recommendations to guide future sustainability activities, public policy campaigns, and implementation pilots. The group identified and explored different pathways of community-based detection using electronic health records, from different international health-care systems, to detect and surveil individuals with early possible cognitive impairment.
AB - Preliminary estimates suggest that current global health-care systems lack the resource capacity to provide persons with dementia timely access to diagnosis, treatment, and care. There is an increasing need to improve timely identification of individuals who will likely progress to Alzheimer's disease (AD) dementia particularly among under-represented, underserved, and vulnerable populations. The rapidly evolving area of bioinformatics of health system data and the emergence of fluid-based biomarkers for pre-symptomatic AD may provide an innovative strategic option for health system planners. A think-tank style meeting entitled “The Campaign to Prevent Alzheimer's Disease Work Group on Community-Based Detection and Assessment of Cognitive Decline” developed recommendations to guide future sustainability activities, public policy campaigns, and implementation pilots. The group identified and explored different pathways of community-based detection using electronic health records, from different international health-care systems, to detect and surveil individuals with early possible cognitive impairment.
UR - http://www.scopus.com/inward/record.url?scp=85142400910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142400910&partnerID=8YFLogxK
U2 - 10.1002/alz.12837
DO - 10.1002/alz.12837
M3 - Article
C2 - 36314503
AN - SCOPUS:85142400910
SN - 1552-5260
VL - 18
SP - 2375
EP - 2381
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 11
ER -